Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Sinzinger, H; Ulm, MR; Neumann, I; Kritz, H; O'Grady, J; Peskar, BA.
The prostacyclin stimulating plasma factor activity improves thromboresistance only if vascular PGI2-production is intact.
Thromb Res. 1996; 84(6):475-480
Doi: 10.1016%2FS0049-3848%2896%2900215-0
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Co-Autor*innen der Med Uni Graz
- Peskar Bernhard
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- PGI2 is important in regulating platelet vessel wall interaction (1). In perfusion chamber experiments the amount of PGI2 formed was inversely related to the amount of platelets deposited (2). In 1978 a plasma factor was described which stimulates vascular PGI2-production (3). In later years, this activity has been monitored in different patient groups (for review see 4). Interestingly, it has been found that diseases associated with an increased bleeding tendency such as uraemia (5) or hepatic failure (6) were associated with an increased PF-activity while others with an enhanced thrombophilia sometimes show an absence of PF-activity (7). Recently, the PGI2 stimulating plasma factor has been purified and cloned (8). It was the aim of these experiments to assess whether PF-activity plays a role in local hemostasis regulation under in-vivo flow conditions and whether this is dependent on the presence of an intact PGI2-formation.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Animals -
- Blood Coagulation -
- Blood Platelets - physiology
- Epoprostenol - pharmacology
- Female - pharmacology
- Humans - pharmacology
- Male - pharmacology
- Middle Aged - pharmacology
- Rabbits - pharmacology
- Find related publications in this database (Keywords)
- Thromboresistance
- Atherosclerosis
- Prostaglandin I-2
- Prostacyclin Stimulating Plasma Factor
- Platelets
- Vascular Wall